X4 Pharmaceuticals (United States)

X4 Pharmaceuticals is a biopharmaceutical company developing novel therapies for rare diseases by targeting the CXCR4 pathway. Based in Boston, the company created Xolremdi (mavorixafor) for WHIM syndrome, a rare immunodeficiency disorder. X4’s CXCR4 inhibitor research addresses immune dysregulation in rare genetic conditions.